TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
- Tuesday, May 15, 2018, 4:32
- Finance
- Add a comment
JACKSONVILLE, Fla., May 15, 2018 /PRNewswire/ — TapImmune Inc. (NASDAQ: TPIV) (“TapImmune”) today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. (“Marker”), a privately-held clinical-stage developer of a transformative,…
Source: https://www.prnewswire.com/news-releases/tapimmune-and-marker-therapeutics-announce-entry-into-merger-agreement-creating-a-transformational-immuno-oncology-platform-300648328.html
About the Author
adminasapcorp has written 38437 stories on this site.